Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 221-224

  Flanagan, Shawn D ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Caco 2 cells; Furosemide; Indomethacin; Intestinal transport; Rat jejunum

Indexed keywords

CYCLOSPORIN; DIURETIC AGENT; FUROSEMIDE; INDOMETACIN; PROBENECID; VINBLASTINE SULFATE;

ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE SECRETION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATED ORGAN; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TEMPERATURE DEPENDENCE;

EID: 0033014877     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018868123367     Document Type: Article

References (28)

1. 1. E. Jackson. Diuretics. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th Edition, J. Hardman, L. Limbird, P. Molinoff, R. Ruddon, and A. G. Gilman (eds.), McGraw-Hill, New York, 1996, pp. 685-713.
2. 2. M. Hammarlund-Udenaes and L. Z. Benet. Furosemide pharmacokinetics and pharmacodynamics in health and disease - An update. J. Pharmacokin. Biopharm. 17:1-46 (1989).
3. 3. M. R. Kelly, R. E. Cutler, A. W. Forrey, and B. M. Kimpel. Pharmacokinetics of orally administered furosemide. Clin. Pharmacol. Ther. 15:178-86 (1974).
4. 4. H. Bundgaard, T. Noørgaard, and N. M. Nielsen. Photodegradation and hydrolysis of furosemide and furosemide esters in aqueous solutions. Int. J. Pharm. 42:217-24 (1988).
5. 5. R. K. Verbeeck, R. V. Patwardhan, J.-P. Villeneuve, G. R. Wilkinson, and R. A. Branch. Furosemide disposition in cirrhosis. Clin. Pharmacol. Ther. 31:719-25 (1982).
6. 6. M. G. Lee and W. L. Chiou. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J. Pharmacokin. Biopharm. 11:623-40 (1983).
7. 7. J. Valentine, D. C. Brater, and G. J. Krejs. Clearance of furosemide by the gastrointestinal tract. J. Pharmacol. Exp. Ther. 236:177-80 (1986).
8. 8. D. E. Smith and L. Z. Benet. Biotransformation of furosemide in kidney transplant patients. Eur. J. Clin. Pharmacol. 24:787-90 (1983).
9. 9. V. Pichette and P. du Soich. Role of the kidneys in the metabolism of furosemide: Its inhibition by probenecid. J. Am. Soc. Nephrol. 7:345-9 (1996).
10. 10. M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, C. L. Marsh, J. P. McVicar, D. M. Barr, B. S. Gillies, and K. E. Thummel. First-pass metabolism of miduzolam by the human intestine. Clin. Pharmacol. Ther. 60:14-24 (1996).
11. 11. U. Mayer, E. Wagenaar, J. H. Beijnen, J. W. Smit, D. K. F. Meijer, J. van Aspereren, P. Borst, and A. Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1038-44 (1996).
12. 12. C. Y. Wu, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:492-7 (1995).
13. 13. F. Thiebaut, T. Tsuro, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue. Proc. Nat. Acad. Sci., USA 84:7735-38 (1987).
14. 14. P. Watkins. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Del. Rev. 27:161-70 (1997).
15. 15. D. E. Smith, W. L. Gee, D. C. Brater, E. Lin, and L. Z. Benet. Preliminary evaluation of furosemide-probenecid interaction in humans. J. Pharm. Sci. 69:571-5 (1980).
16. 16. H. Saitoh and B. J. Aungst. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12:1304-10 (1995).
17. 17. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-49 (1989).
18. 18. A. Hilgers, R. A. Conradi, and P. S. Burton. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7:902-10 (1990).
19. 19. F. Delie and W. Rubas. A human colonic cell line sharing similarities with eneterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit. Rev. Therap. Drug Carrier Sys. 14:221-85 (1997).
20. 20. D. E. Smith, D. C. Brater, E. Lin, and L. Z. Benet. Attenuation of furosemide's pharmacokinetic effect by indomethacin: Pharmacokinetic evaluation. J. Pharmacokin. Biopharm. 7:265-74 (1979).
21. 21. R. Bendayan. Renal drug transport: A review. Pharmacotherapy 16:971-85 (1996).
22. 22. G. K. Collington, J. Hunter, C. N. Allen, N. L. Simmons, and B. H. Hirst. Polarized efflux of 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers. Biochem. Pharmacol. 44:417-24 (1992).
23. 23. H. Saitoh, C. Gerard, and B. J. Aungst. The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: A mechanism contributing to poor oral absorption. J. Pharmacol. Exp. Ther. 278:205-11 (1996).
24. 24. M. P. Draper, R. L. Martell, and S. B. Levy. Indomethacin-mediated reversal of multidrug reistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 75:810-15 (1997).
25. 25. M. Kool, M. de Haas, G. L. Scheffer, R. J. Scheper, M. van Eijk, J. A. Juijn, F. Baas, and P. Borst. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP-5, homologues of the multidrug resistance-associated protein gene (MRP-1), in human cancer cell lines. Cancer Res. 57:3537-47 (1997).
26. 26. Z. Holló, L. Homolya, T. Hegedús, and B. Sarkadi. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 383:99-104 (1996).
27. 27. R. Evers, G. Zaman, L. van Deetmer, H. Jansen, J. Calafat, L. Oomen, R. Oude Elferink, P. Borst, and A. H. Schinkel. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1211-18 (1996).
28. 28. R. Evers, M. Kool, L. van Deetmer, H. Jansen, J. Calafat, L. Oomen, C. C. Paulusma, R. Oude Elferink, F. Baas, A. H. Schinkel, and P. Borst. Drug export activity of the human canicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:1310-19 (1998).